Condition: Castration Resistant Metastatic Prostate Cancer · Prostate Cancer · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Sponsor: Aktis Oncology, Inc.
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).
This description comes directly from the study's public registry record.
Tiffany Wang, MD · +1-857-216-8482 · AKY-2519-01inquiries@aktisoncology.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital Presbyterian | Irvine, California, United States | Recruiting |
| Biogenix Molecular, LLC | Miami, Florida, United States | Recruiting |
| BAMF Health | Grand Rapids, Michigan, United States | Recruiting |
| XCancer | Omaha, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07581184